DISC MEDICINE, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 35.58 USD | +4.79% |
|
+3.02% | -38.18% |
| May. 09 | Disc Medicine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Apr. 08 | Stifel Raises Price Target on Disc Medicine to $73 From $71, Keeps Buy Rating | MT |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 839M |
|---|---|---|---|---|---|
| Net income 2024 * | -119M | Net income 2025 * | -145M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 365M | Net cash position 2025 * | 358M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-7.19
x | P/E ratio 2025 * |
-6.25
x | Employees | 78 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 81.86% |
More Fundamentals
* Assessed data
More news
Latest transcript on Disc Medicine, Inc.
More recommendations
More press releases
| 1 day | +4.89% | ||
| 1 week | +3.40% | ||
| Current month | +5.57% | ||
| 1 month | +20.31% | ||
| 3 months | -51.44% | ||
| 6 months | -35.54% | ||
| Current year | -37.95% |
1 week
32.54
37.16
1 month
28.2537.16
Current year
25.6077.60
1 year
25.6077.60
3 years
15.0077.60
5 years
15.0077.60
10 years
15.0077.60
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +4.01% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-03 | 35.7 | +5.17% | 167 140 |
| 24-05-31 | 33.95 | -1.96% | 359,305 |
| 24-05-30 | 34.63 | +1.44% | 257,200 |
| 24-05-29 | 34.14 | -1.50% | 333,122 |
| 24-05-28 | 34.66 | +1.11% | 604,950 |
Delayed Quote Nasdaq, June 03, 2024 at 12:23 pm EDT
More quotes
Disc Medicine, Inc. is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The Company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps) including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. It is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.
Calendar
2024-06-06
- Jefferies Global Healthcare Conference
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
33.95
USD
Average target price
57.33
USD
Spread / Average Target
+68.88%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -37.95% | 839M | |
| +46.02% | 54.63B | |
| -6.72% | 39.92B | |
| +37.07% | 38.82B | |
| +13.26% | 26.86B | |
| -11.17% | 26.22B | |
| -21.60% | 18.78B | |
| +25.24% | 12.21B | |
| +0.39% | 12.16B | |
| +25.73% | 11.94B |
- Stock Market
- Equities
- IRON Stock
